Comprehensive Stock Comparison
Compare Valneva SE (VALN) vs BioNTech SE (BNTX) vs Moderna, Inc. (MRNA) vs Summit Therapeutics Inc. (SMMT) vs Vaxcyte, Inc. (PCVX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | VALN | 10.3% revenue growth vs MRNA's -53.3% |
| Quality / Margins | BNTX | -18.1% net margin vs MRNA's -140.3% |
| Stability / Safety | PCVX | Beta 0.77 vs SMMT's 1.40 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MRNA | +73.0% vs SMMT's -19.8% |
| Efficiency (ROA) | BNTX | -2.7% ROA vs SMMT's -143.7%, ROIC -10.5% vs -163.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Valneva is a specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. It generates revenue primarily from sales of its commercial travel vaccines — IXIARO for Japanese encephalitis and DUKORAL for cholera — while advancing a pipeline of late-stage candidates including a chikungunya vaccine and a Lyme disease vaccine in partnership with Pfizer. The company's competitive advantage lies in its focus on niche infectious diseases often overlooked by larger pharmaceutical companies and its strategic partnerships that provide development funding and commercialization expertise.
BioNTech is a biotechnology company that develops mRNA-based immunotherapies for cancer and infectious diseases. It generates revenue primarily through COVID-19 vaccine sales — which accounted for the vast majority of its income during the pandemic — and through partnerships and licensing deals for its oncology pipeline. The company's key advantage is its pioneering mRNA technology platform, which enables rapid development of targeted therapies and vaccines.
Moderna is a biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines for infectious diseases, cancer, and other serious conditions. It generates revenue primarily from vaccine sales—notably its COVID-19 vaccine—with additional income from research collaborations and government grants. The company's key advantage is its proprietary mRNA technology platform, which enables rapid development of new vaccines and therapeutics compared to traditional methods.
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat serious infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with its lead candidate ridinilazole in Phase III trials for C. difficile infection — while pursuing future commercialization of its pipeline. The company's competitive advantage lies in its targeted approach to antibiotic-resistant infections and its clinical-stage assets addressing significant unmet medical needs.
Vaxcyte is a clinical-stage biotechnology company developing novel protein vaccines to prevent bacterial infectious diseases. It currently generates no revenue from product sales — relying on research funding and partnerships — but aims to commercialize its lead pneumococcal conjugate vaccine candidate, VAX-24, which is in Phase 1/2 clinical trials. The company's key advantage is its proprietary cell-free protein synthesis platform, which enables rapid design and production of complex vaccine candidates that are difficult to manufacture using traditional methods.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
VALN leads in 2 of 6 categories (Financial Metrics, Valuation Metrics). SMMT leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
BNTX and PCVX operate at a comparable scale, with $3.2B and $0 in trailing revenue. BNTX is the more profitable business, keeping -18.1% of every revenue dollar as net income compared to MRNA's -140.3%. On growth, VALN holds the edge at +27.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VALNValneva SE | BNTXBioNTech SE | MRNAModerna, Inc. | SMMTSummit Therapeuti… | PCVXVaxcyte, Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $196M | $3.2B | $2.2B | $0 | $0 |
| EBITDAEarnings before interest/tax | -$36M | -$550M | -$3.3B | -$812M | -$899M |
| Net IncomeAfter-tax profit | -$67M | -$572M | -$3.1B | -$1.1B | -$767M |
| Free Cash FlowCash after capex | -$34M | -$563M | -$2.7B | -$324M | -$669M |
| Gross MarginGross profit ÷ Revenue | +49.0% | +82.5% | +11.9% | — | — |
| Operating MarginEBIT ÷ Revenue | -25.6% | -29.6% | -155.9% | — | — |
| Net MarginNet income ÷ Revenue | -34.1% | -18.1% | -140.3% | — | — |
| FCF MarginFCF ÷ Revenue | -17.5% | -17.8% | -119.9% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.0% | +22.0% | -45.2% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +60.5% | -114.8% | -16.6% | -2.4% | -61.9% |
Valuation Metrics
| Metric | VALNValneva SE | BNTXBioNTech SE | MRNAModerna, Inc. | SMMTSummit Therapeuti… | PCVXVaxcyte, Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $963M | $27.7B | $20.9B | $12.9B | $8.1B |
| Enterprise ValueMkt cap + debt − cash | $1.0B | $16.4B | $19.8B | $12.7B | $8.0B |
| Trailing P/EPrice ÷ TTM EPS | -55.31x | -33.74x | -5.78x | -11.52x | -10.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 26.27x | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.82x | 8.52x | 6.55x | — | — |
| Price / BookPrice ÷ Book value/share | 3.64x | 1.16x | 1.89x | 18.83x | 3.13x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
BNTX delivers a -3.1% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-164 for SMMT. BNTX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to VALN's 1.19x. On the Piotroski fundamental quality scale (0–9), VALN scores 5/9 vs PCVX's 1/9, reflecting solid financial health.
| Metric | VALNValneva SE | BNTXBioNTech SE | MRNAModerna, Inc. | SMMTSummit Therapeuti… | PCVXVaxcyte, Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -36.0% | -3.1% | -33.4% | -163.9% | -28.5% |
| ROA (TTM)Return on assets | -14.2% | -2.7% | -25.7% | -143.7% | -25.5% |
| ROICReturn on invested capital | +4.5% | -10.5% | -27.0% | -163.4% | -24.7% |
| ROCEReturn on capital employed | +3.9% | -6.4% | -28.9% | -151.5% | -29.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 4 | 1 | 1 |
| Debt / EquityFinancial leverage | 1.19x | 0.01x | 0.07x | 0.03x | 0.04x |
| Net DebtTotal debt minus cash | $48M | -$9.5B | -$1.2B | -$204M | -$56M |
| Cash & Equiv.Liquid assets | $168M | $9.8B | $1.9B | $225M | $174M |
| Total DebtShort + long-term debt | $216M | $254M | $747M | $21M | $117M |
| Interest CoverageEBIT ÷ Interest expense | -1.75x | -49.09x | -393.13x | — | — |
Total Returns (with DRIP)
A $10,000 investment in SMMT five years ago would be worth $25,060 today (with dividends reinvested), compared to $3,403 for MRNA. Over the past 12 months, MRNA leads with a +73.0% total return vs SMMT's -19.8%. The 3-year compound annual growth rate (CAGR) favors SMMT at 109.7% vs MRNA's -27.2% — a key indicator of consistent wealth creation.
| Metric | VALNValneva SE | BNTXBioNTech SE | MRNAModerna, Inc. | SMMTSummit Therapeuti… | PCVXVaxcyte, Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +23.8% | +14.0% | +73.6% | -5.3% | +32.9% |
| 1-Year ReturnPast 12 months | +64.3% | -2.4% | +73.0% | -19.8% | -15.4% |
| 3-Year ReturnCumulative with dividends | -5.3% | -15.2% | -61.4% | +821.7% | +50.7% |
| 5-Year ReturnCumulative with dividends | -58.0% | +1.9% | -66.0% | +150.6% | +139.0% |
| 10-Year ReturnCumulative with dividends | -58.0% | +688.9% | +188.0% | +145.8% | +136.1% |
| CAGR (3Y)Annualised 3-year return | -1.8% | -5.4% | -27.2% | +109.7% | +14.6% |
Risk & Volatility
PCVX is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than SMMT's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRNA currently trades 97.0% from its 52-week high vs SMMT's 44.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VALNValneva SE | BNTXBioNTech SE | MRNAModerna, Inc. | SMMTSummit Therapeuti… | PCVXVaxcyte, Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 0.92x | 1.25x | 1.40x | 0.77x |
| 52-Week HighHighest price in past year | $12.25 | $124.00 | $55.20 | $36.91 | $76.61 |
| 52-Week LowLowest price in past year | $5.43 | $81.20 | $22.28 | $13.83 | $27.66 |
| % of 52W HighCurrent price vs 52-week peak | +90.5% | +88.9% | +97.0% | +44.9% | +80.6% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 50.2 | 71.6 | 50.1 | 62.8 |
| Avg Volume (50D)Average daily shares traded | 14K | 822K | 10.8M | 2.3M | 1.2M |
Analyst Outlook
Analyst consensus: VALN as "Buy", BNTX as "Buy", MRNA as "Hold", SMMT as "Buy", PCVX as "Buy". Consensus price targets imply 65.3% upside for VALN (target: $18) vs -34.9% for MRNA (target: $35).
| Metric | VALNValneva SE | BNTXBioNTech SE | MRNAModerna, Inc. | SMMTSummit Therapeuti… | PCVXVaxcyte, Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $18.33 | $136.80 | $34.89 | $26.00 | $83.00 |
| # AnalystsCovering analysts | 2 | 24 | 27 | 20 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| Valneva SE (VALN) | 100 | 34.65 | -65.4% |
| BioNTech SE (BNTX) | 100 | 52.82 | -47.2% |
| Moderna, Inc. (MRNA) | 100 | 23.04 | -77.0% |
| Summit Therapeutics… (SMMT) | 100 | 176.86 | +76.9% |
| Vaxcyte, Inc. (PCVX) | 100 | 271.91 | +171.9% |
Summit Therapeutics… (SMMT) returned +151% over 5 years vs Moderna, Inc. (MRNA)'s -66%. A $10,000 investment in SMMT 5 years ago would be worth $25,060 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Valneva SE (VALN) | $94M | $170M | +80.3% |
| BioNTech SE (BNTX) | $62M | $2.8B | +4366.2% |
| Moderna, Inc. (MRNA) | $108M | $3.2B | +2851.2% |
| Summit Therapeutics… (SMMT) | $3M | $0.00 | -100.0% |
| Vaxcyte, Inc. (PCVX) | $0.00 | $0.00 | — |
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Valneva SE (VALN) | -26.3% | -7.2% | +72.6% |
| BioNTech SE (BNTX) | -139.1% | -24.2% | +82.6% |
| Moderna, Inc. (MRNA) | -199.5% | -111.3% | +44.2% |
| Summit Therapeutics… (SMMT) | -19.0% | -111.9% | -488.8% |
Valneva SE's net margin went from -26% (2015) to -7% (2024).
Chart 4P/E Ratio History — 3 Years
| Stock | 2021 | 2023 | Change |
|---|---|---|---|
| BioNTech SE (BNTX) | 6.3 | 27.6 | +338.1% |
BioNTech SE has traded in a 4x–28x P/E range over 3 years; current trailing P/E is ~-34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Valneva SE (VALN) | -1.32 | -0.17 | +87.1% |
| BioNTech SE (BNTX) | -0.38 | -2.77 | -628.9% |
| Moderna, Inc. (MRNA) | -3.79 | -9.27 | -144.6% |
| Summit Therapeutics… (SMMT) | -0.43 | -1.44 | -234.9% |
| Vaxcyte, Inc. (PCVX) | -4.83 | -5.63 | -16.6% |
Chart 6Free Cash Flow — 5 Years
Valneva SE generated $-84M FCF in 2024 (-414% vs 2021). BioNTech SE generated $-245M FCF in 2024 (-133% vs 2021).
VALN vs BNTX vs MRNA vs SMMT vs PCVX: Key Questions Answered
7 questions · data-driven answers · updated daily
01Is VALN or BNTX or MRNA or SMMT or PCVX a better buy right now?
Analysts rate Valneva SE (VALN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VALN or BNTX or MRNA or SMMT or PCVX?
Over the past 5 years, Summit Therapeutics Inc. (SMMT) delivered a total return of +150.6%, compared to -66.0% for Moderna, Inc. (MRNA). A $10,000 investment in SMMT five years ago would be worth approximately $25K today (assuming dividends reinvested). Over 10 years, the gap is even starker: BNTX returned +688.9% versus VALN's -58.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VALN or BNTX or MRNA or SMMT or PCVX?
By beta (market sensitivity over 5 years), Vaxcyte, Inc. (PCVX) is the lower-risk stock at 0.77β versus Summit Therapeutics Inc.'s 1.40β — meaning SMMT is approximately 82% more volatile than PCVX relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 119% for Valneva SE — giving it more financial flexibility in a downturn.
04Which has better profit margins — VALN or BNTX or MRNA or SMMT or PCVX?
Summit Therapeutics Inc. (SMMT) is the more profitable company, earning 0.0% net margin versus -111.3% for Moderna, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VALN leads at 7.9% versus -123.3% for MRNA. At the gross margin level — before operating expenses — BNTX leads at 80.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — VALN or BNTX or MRNA or SMMT or PCVX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is VALN or BNTX or MRNA or SMMT or PCVX better for a retirement portfolio?
For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.92), +688.9% 10Y return). Both have compounded well over 10 years (BNTX: +688.9%, SMMT: +145.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between VALN and BNTX and MRNA and SMMT and PCVX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.